|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Providence Health Care AstraZeneca |
| Information provided by: | Providence Health Care |
| ClinicalTrials.gov Identifier: | NCT00320970 |
Purpose
Diabetic nephropathy is a frequent microvascular complication that occurs in approximately 40% of patients with either type 1 or type 2 diabetes. The most common cause of end-stage renal disease (ESRD) in the United States and in the developed world is diabetic nephropathy. Currently, more than half the United States ESRD population has diabetes. More effective therapies to prevent and treat diabetic nephropathy are urgently needed. One way to increase therapeutic effectiveness is to refine treatment targets based on improved understanding of how treatments modulate disease processes. The purpose of this study is to determine whether a treatment for diabetic nephropathy, the angiotensin receptor blocker candesartan, modifies mediators of kidney injury independent of blood pressure and the relationships to drug dose.
| Condition | Intervention |
|
Diabetic Nephropathy Hypertension |
Drug: Candesartan |
| MedlinePlus related topics: | Diabetes Diabetic Kidney Problems High Blood Pressure |
| Drug Information available for: | Candesartan cilexetil CV 11974 Angiotensin II Angiotensin II, ile(5)- |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Pharmacokinetics/Dynamics Study |
| Official Title: | Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study |
| Estimated Enrollment: | 36 |
| Study Start Date: | August 2002 |
| Estimated Study Completion Date: | September 2004 |
![]() |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Washington | |||||
| Providence Medical Research Center | |||||
| Spokane, Washington, United States, 99204 | |||||
| Providence Health Care |
| AstraZeneca |
| Principal Investigator: | Katherine R. Tuttle, MD,FASN,FACP | Providence Medical Research Center |
More Information
Click here for more information regarding Providence Medical Research Center 
  |
| Study ID Numbers: | HI831 |
| First Received: | April 28, 2006 |
| Last Updated: | August 1, 2007 |
| ClinicalTrials.gov Identifier: | NCT00320970 |
| Health Authority: | United States: Institutional Review Board |
|
|
|
|
|